MX2015011549A - Entidades quimicas. - Google Patents

Entidades quimicas.

Info

Publication number
MX2015011549A
MX2015011549A MX2015011549A MX2015011549A MX2015011549A MX 2015011549 A MX2015011549 A MX 2015011549A MX 2015011549 A MX2015011549 A MX 2015011549A MX 2015011549 A MX2015011549 A MX 2015011549A MX 2015011549 A MX2015011549 A MX 2015011549A
Authority
MX
Mexico
Prior art keywords
chemical entities
compositions
treatment
atr
solvates
Prior art date
Application number
MX2015011549A
Other languages
English (en)
Other versions
MX368056B (es
Inventor
Fernandez Joaquín Pastor
González Sonia Martínez
Aparicio Carmen Blanco
Ruiz Oscar Fernández-Capetillo
Ferreira María Del Rosario Rico
Lázaro Luis Ignacio Toledo
Arísteguí Sonsoles Rodríguez
Costa Matilde Murga
Busto Carmen Varela
Contreras Andrés Joaquín Lopez
Oliver Renner
Soler María Nieto
Muñoz David Alvaro Cebrián
Original Assignee
Fundación Ct Nac De Investigaciones Oncológicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013903&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015011549(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundación Ct Nac De Investigaciones Oncológicas Carlos Iii filed Critical Fundación Ct Nac De Investigaciones Oncológicas Carlos Iii
Publication of MX2015011549A publication Critical patent/MX2015011549A/es
Publication of MX368056B publication Critical patent/MX368056B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se proporcionan entidades químicas seleccionadas de los compuestos de fórmula (I), (ver Fórmula) en la que R1, R2 y m tienen los significados dados en la descripción, y sales, solvatos y estereoisómeros farmacéuticamente aceptables de los mismos, que son inhibidores de ATR y son potencialmente útiles en el tratamiento del cáncer. Se proporcionan adicionalmente composiciones farmacéuticas de las entidades químicas, productos de combinación que contienen las entidades químicas, el uso de las composiciones como agentes terapéuticos y procedimientos de tratamiento que usan estas composiciones.
MX2015011549A 2013-03-15 2014-03-14 Compuestos tricíclicos inhibidores de atr (cinasa de ataxia telangiectasia mutada y rad-3. MX368056B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382089 2013-03-15
PCT/GB2014/050825 WO2014140644A1 (en) 2013-03-15 2014-03-14 Chemical entities

Publications (2)

Publication Number Publication Date
MX2015011549A true MX2015011549A (es) 2016-05-31
MX368056B MX368056B (es) 2019-09-18

Family

ID=48013903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011549A MX368056B (es) 2013-03-15 2014-03-14 Compuestos tricíclicos inhibidores de atr (cinasa de ataxia telangiectasia mutada y rad-3.

Country Status (32)

Country Link
US (1) US9453031B2 (es)
EP (1) EP2970332B1 (es)
JP (1) JP6379115B2 (es)
KR (1) KR102206318B1 (es)
CN (1) CN105051047B (es)
AR (1) AR095443A1 (es)
AU (1) AU2014229735B2 (es)
BR (1) BR112015023060B1 (es)
CA (1) CA2904768C (es)
CL (1) CL2015002591A1 (es)
CY (1) CY1120619T1 (es)
DK (1) DK2970332T3 (es)
EA (1) EA029771B1 (es)
ES (1) ES2670674T3 (es)
HK (1) HK1215021A1 (es)
HR (1) HRP20180839T1 (es)
HU (1) HUE037685T2 (es)
IL (1) IL240708B (es)
LT (1) LT2970332T (es)
MX (1) MX368056B (es)
NO (1) NO2970332T3 (es)
NZ (1) NZ711038A (es)
PE (1) PE20152007A1 (es)
PH (1) PH12015502159B1 (es)
PL (1) PL2970332T3 (es)
PT (1) PT2970332T (es)
RS (1) RS57216B1 (es)
SG (1) SG11201507555PA (es)
SI (1) SI2970332T1 (es)
TW (1) TWI557131B (es)
UA (1) UA118261C2 (es)
WO (1) WO2014140644A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016112374A2 (en) * 2015-01-09 2016-07-14 The General Hospital Corporation Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017202748A1 (en) * 2016-05-24 2017-11-30 Merck Patent Gmbh Tricyclic heterocylic derivatives
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
BR112020016020A8 (pt) 2018-02-07 2023-04-25 Shijiazhuang Sagacity New Drug Dev Company Ltd Inibidor de atr e aplicação do mesmo
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN113004303A (zh) * 2019-12-18 2021-06-22 江苏恒瑞医药股份有限公司 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
WO2021143821A1 (zh) * 2020-01-17 2021-07-22 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
US20240025899A1 (en) 2020-10-16 2024-01-25 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN115286645A (zh) * 2022-08-16 2022-11-04 南京雷正医药科技有限公司 三环杂环衍生物及其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
AU3427093A (en) 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
NZ337750A (en) 1997-02-12 2001-08-31 Univ Michigan Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1167422C (zh) 1999-02-10 2004-09-22 阿斯特拉曾尼卡有限公司 用作血管生成抑制剂的喹唑啉衍生物
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
WO2001060814A2 (en) 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
AU6623201A (en) 2000-07-07 2002-02-05 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
EP2079744A1 (en) * 2006-10-30 2009-07-22 Novartis AG Imidazopyridazines as pi3k lipid kinase inhibitors
EA200901488A1 (ru) * 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
MX2012002059A (es) * 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
JP2013529643A (ja) * 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体
TWI441824B (zh) * 2010-12-16 2014-06-21 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法

Also Published As

Publication number Publication date
PE20152007A1 (es) 2016-02-04
TWI557131B (zh) 2016-11-11
MX368056B (es) 2019-09-18
CA2904768C (en) 2021-07-27
NO2970332T3 (es) 2018-07-28
IL240708A0 (en) 2015-10-29
LT2970332T (lt) 2018-06-11
AU2014229735B2 (en) 2018-08-09
US20160024112A1 (en) 2016-01-28
CY1120619T1 (el) 2019-12-11
EA029771B1 (ru) 2018-05-31
HUE037685T2 (hu) 2018-09-28
HRP20180839T1 (hr) 2018-06-29
WO2014140644A1 (en) 2014-09-18
UA118261C2 (uk) 2018-12-26
CN105051047B (zh) 2017-12-15
AU2014229735A1 (en) 2015-09-03
EA201591781A1 (ru) 2016-02-29
AR095443A1 (es) 2015-10-14
KR102206318B1 (ko) 2021-01-25
SG11201507555PA (en) 2015-10-29
IL240708B (en) 2019-08-29
PH12015502159A1 (en) 2016-01-25
CL2015002591A1 (es) 2016-02-05
CA2904768A1 (en) 2014-09-18
JP6379115B2 (ja) 2018-08-22
KR20150129741A (ko) 2015-11-20
PL2970332T3 (pl) 2018-08-31
BR112015023060B1 (pt) 2022-07-05
PH12015502159B1 (en) 2016-01-25
BR112015023060A2 (pt) 2017-07-18
JP2016510803A (ja) 2016-04-11
ES2670674T3 (es) 2018-05-31
TW201446772A (zh) 2014-12-16
CN105051047A (zh) 2015-11-11
PT2970332T (pt) 2018-05-25
NZ711038A (en) 2020-02-28
EP2970332A1 (en) 2016-01-20
SI2970332T1 (en) 2018-06-29
EP2970332B1 (en) 2018-02-28
HK1215021A1 (zh) 2016-08-12
RS57216B1 (sr) 2018-07-31
DK2970332T3 (en) 2018-05-22
US9453031B2 (en) 2016-09-27

Similar Documents

Publication Publication Date Title
PH12015502159A1 (en) Chemical entities
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
PH12017502141A1 (en) Compounds and their methods of use
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2017000408A (es) Compuestos antiproliferativos y métodos de uso de los mismos.
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12015501609A1 (en) Phenicol antibacterials
MX2013010898A (es) Novedoso derivados de la pirimidina.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
TW201613864A (en) Novel compounds
GB201209587D0 (en) Therapeutic compounds
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2015012386A (es) Inhibidores de la cinasa cdk9.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
IN2015DN02109A (es)
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.

Legal Events

Date Code Title Description
FG Grant or registration